| neratinib based treatment | pertuzumab based treatment | trastuzumab based treatment | tucatinib based treatment |
| neratinib | neratinib plus capecitabine | pertuzumab plus trastuzumab | pertuzumab plus trastuzumab plus docetaxel | trastuzumab plus endocrine therapy | tucatinib plus trastuzumab plus capecitabine |
la/mBC - HER2 positive | | | | | | |
la/mBC - HER2 positive - (neo)adjuvant (NA) | | | | | | |
la/mBC - HER2 positive - 1st Line (L1) 5 | | | | | | |
la/mBC - HER2 positive - 2nd Line (L2) 13 | | | | | | |